Beta notice: PeptiJournal is currently in beta. Calculator math and RUO research protocol summaries should be independently double-checked against source literature before use in any research workflow.

    §FertilityResearch protocol

    HMG.

    Human Menopausal Gonadotropin (HMG) is a purified gonadotropin preparation containing equal amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity[1][2]. In males, HMG ...

    Last updated:

    Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.

    Calculated-volume support unavailable

    This selected cited guide does not contain one unambiguous vial, per-event amount, cadence, and diluent set. No value was inferred from general library metadata. Review the cited table below before creating a private Research Use Only record.

    Cited protocol & reconstitution guide

    Source-backed reference fields by phase, including any volume fields authored in the cited guide.

    Weeks 1–12

    75 IU (0.15 mg)

    Units / volume3.0 mL (300 units)

    Weeks 13–16 (optional extension)

    75 IU (0.15 mg)

    Units / volume3.0 mL (300 units)

    Overview

    Overview

    Human Menopausal Gonadotropin (HMG) is a purified gonadotropin preparation containing equal amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity[1][2]. In males, HMG is used alongside hCG to stimulate spermatogenesis in cases of hypogonadotropic hypogonadism or infertility[3][4]. This educational protocol presents a thrice-weekly subcutaneous approach for male fertility support. Reconstitute: Add 3.0 mL bacteriostatic water → 25 IU/mL concentration. Typical protoc

    Category
    Fertility
    Routes
    subcutaneous

    Mechanism

    HMG

    Mechanism of action

    Mechanism of action

    HMG provides both FSH and LH activity in a 1:1 ratio, derived from purified human menopausal urine [1] [2] . In males with hypogonadotropic hypogonadism, FSH stimulation is essential for spermatogenesis (sperm production) [3] . When hCG alone fails to induce adequate sperm production, adding HMG provides the necessary FSH activity to support testicular function and fertility [5] [6] . Clinical studies demonstrate that HMG combined with hCG significantly improves sperm parameters including motility, morphology, and concentration, with enhanced pregnancy rates in treated couples [7] [12] .

    Key research findings
    • 01

      Not a single peptide but a purified gonadotropin preparation, classically extracted from the urine of postmenopausal women, supplying both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity (established biochemistry).

    • 02

      Standardized by bioassay in international units (IU) of FSH and LH rather than by mass, reflecting its origin as a biological extract (established pharmacology).

    • 03

      FSH activity acts on gonadal FSH receptors to support follicular development/gametogenesis while LH activity supports steroidogenesis; the combined action is well studied in reproductive medicine (human study).

    • 04

      Some preparations include added hCG to standardize LH-like activity, because hCG and LH act on the same receptor (established formulation science).

    • 05

      As a biologically sourced product, its composition and purity depend on the manufacturing process; highly purified and recombinant gonadotropins have been developed and compared against urinary HMG in reproductive research (human study).

    Primary source: HMG has a long, mature clinical-research history in reproductive medicine as a combined FSH/LH preparation, with extensive human study of gonadal stimulation. Because it is a urine-derived biological extract rather than a defined synthetic peptide, its characterization centers on standardized bioactivity; on this platform it is handled strictly as a research material.

    Protocol Reference

    Protocol reference

    Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.
    subcutaneous

    Commonly cited research range: 75–75 mcg, daily_for_cycles.

    Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.

    Cited protocol & reconstitution guide

    Source-backed reference fields by phase, including any volume fields authored in the cited guide.

    Weeks 1–12

    75 IU (0.15 mg)

    Units / volume3.0 mL (300 units)

    Weeks 13–16 (optional extension)

    75 IU (0.15 mg)

    Units / volume3.0 mL (300 units)

    Storage & Handling

    Storage requirements(typical for most peptides)

    ❄️
    Lyophilized (powder)
    -20°C (frozen)

    Can be stored for extended periods. Protect from moisture.

    🧊
    Reconstituted
    2-8°C (refrigerated)

    Store in refrigerator door. Never freeze after reconstitution.

    ⏱️
    Stability window
    28-30 days after reconstitution

    Label vials with reconstitution date. Discard if cloudy.

    Reconstitution steps

    1. 01🌡️Draw 3.0 mL bacteriostatic water with a sterile 3 mL syringe.
    2. 02🧴Inject slowly down the vial wall to avoid foaming.
    3. 03💉Gently swirl or roll the vial until fully dissolved (do not shake).
    4. 04💧Label with date and time; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
    5. 05🔄For optimal potency, use reconstituted solution promptly or within a few days[9].
    6. 06🏷️Important: This guide is for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. For research use only.

    Additional storage notes

    Lyophilized (unopened)

    Store at 2–8 °C (35.6–46.4 °F) away from light; stable at controlled room temperature up to 25 °C (77 °F) [9] .

    Reconstituted

    Refrigerate at 2–8 °C (35.6–46.4 °F); for best potency use promptly (official guidance recommends immediate use with plain diluent) [9] .

    With bacteriostatic water, reconstituted solution may be refrigerated and used within a few days.

    Protect from light at all times; discard any unused solution if not used within recommended timeframe.

    Clinical Evidence

    Clinical evidence

    Well studied in reproductive-medicine research for stimulation of gonadal function.

    HMG has a long, mature clinical-research history in reproductive medicine as a combined FSH/LH preparation, with extensive human study of gonadal stimulation. Because it is a urine-derived biological extract rather than a defined synthetic peptide, its characterization centers on standardized bioactivity; on this platform it is handled strictly as a research material.

    1. 01Not a single peptide but a purified gonadotropin preparation, classically extracted from the urine of postmenopausal women, supplying both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity (established biochemistry).
    2. 02Standardized by bioassay in international units (IU) of FSH and LH rather than by mass, reflecting its origin as a biological extract (established pharmacology).
    3. 03FSH activity acts on gonadal FSH receptors to support follicular development/gametogenesis while LH activity supports steroidogenesis; the combined action is well studied in reproductive medicine (human study).
    4. 04Some preparations include added hCG to standardize LH-like activity, because hCG and LH act on the same receptor (established formulation science).
    5. 05As a biologically sourced product, its composition and purity depend on the manufacturing process; highly purified and recombinant gonadotropins have been developed and compared against urinary HMG in reproductive research (human study).

    Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.

    References

    Literature references

    Published research articles and sources related to HMG.

    1. 01
      Metrovan Urology – hMG (Menotropin) Overview — hMG composition: 1:1 blend of FSH and LH derived from postmenopausal urine; standard preparations provide 75 IU FSH + 75 IU LH per vial View Source
    2. 02
      Menopur® (Menotropins) Product Monograph — Human menopausal gonadotropin for subcutaneous administration; each vial contains 75 IU FSH + 75 IU LH activity View Source
    3. 03
      ASRM Practice Committee 2020 – Gonadotropin Use for Ovulation Induction — Clinical guidance on gonadotropin therapy; low-dose protocols (37.5–75 IU) with careful monitoring View Source
      et al. (2020)
    4. 04
      ASRM Patient Fact Sheet – Medications for Inducing Ovulation — Typical gonadotropin protocols: 75–150 IU injected daily for approximately 7–12 days; course may extend if ovaries respond slowly View Source
    5. 05
      Metrovan Urology – Hormones and Male Infertility Treatment — In hypogonadal men, hMG added at 75–150 IU three times weekly if hCG alone insufficient for spermatogenesis View Source
    6. 06
      Metrovan Urology – Combined hCG and hMG Therapy — hCG given 2–3 times weekly stimulates testosterone; hMG provides FSH activity to stimulate sperm production when FSH deficient View Source
    7. 07
      International Journal of Reproductive BioMedicine (Iran JRM, 2014) — Randomized trial: HMG 75 IU subcutaneously three times weekly for 3 months significantly improved sperm motility and morphology; pregnancy rate 57% vs. control View Source
      et al. (2014)
    8. 08
      Menopur® Monograph – Administration and Reconstitution — Subcutaneous administration for follicular stimulation; each 75 IU vial typically reconstituted in 1 mL diluent for 75 IU/mL concentration View Source
    9. 09
      Menopur® Monograph – Stability and Storage — Lyophilized menotropin stable at room temperature (15–25 °C) away from light; reconstituted solution should be used immediately to ensure potency and sterility View Source
    10. 10
      MedlinePlus – Subcutaneous Injection Instructions — Use short, thin needle for SC injections; insert at 90° angle into pinched fatty tissue (45° if limited subcutaneous fat); do not reuse needles View Source
    11. 11
      MedlinePlus – Injection Site Rotation — Maintain skin health by alternating injection sites at least one inch apart; avoid areas with irritation, scars, or bruises View Source
    12. 12
      Reproductive Medicine and Biology (2018) – Gonadotropin Therapy for Male Infertility — Review of hCG and hMG combination therapy for hypogonadotropic hypogonadism; FSH supplementation critical for spermatogenesis when hCG monotherapy inadequate View Source
      et al. (2018)
    13. 13
      Pure Lab Peptides — HMG 75 IU product page with quality documentation and batch testing information View Source
    Search PubMed for HMG

    Research Considerations

    Research considerations

    Research Use Only - not for human or veterinary therapeutic use. Has been studied in clinical research; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.

    Factors noted in the research literature; not patient-specific medical advice.

    Regulatory Status

    Regulatory status

    RUO

    Research Use Only. PeptiJournal supports private research documentation and calculation support. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.

    Comparisons

    Comparisons

    CompoundMechanismRouteStatus
    HMGthisA purified gonadotropin preparation providing combined FSH and LH activity, acting on gonadal receptors to support gametogenesis and steroidogenesis.subcutaneousInvestigational / RUO
    OxytocinA nonapeptide hormone acting on oxytocin receptors; studied for roles in uterine contraction, lactation, and central modulation of social and affiliative behavior.subcutaneousInvestigational / RUO
    GonadorelinA synthetic form of gonadotropin-releasing hormone (GnRH) acting on pituitary GnRH receptors to stimulate luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, supporting the hypothalamic-pituitary-gonadal axis.subcutaneousInvestigational / RUO
    HCGA glycoprotein hormone that binds LH receptors in the gonads, mimicking luteinizing hormone with a substantially longer half-life to stimulate gonadal steroidogenesis.subcutaneousInvestigational / RUO
    IGF-1 LR3A modified analog of insulin-like growth factor-1 with reduced binding to IGF-binding proteins, giving a markedly extended half-life and prolonged activation of IGF-1 receptor anabolic signaling.subcutaneousInvestigational / RUO
    IpamorelinBinds to ghrelin receptors to stimulate pituitary gland to release growth hormone. Highly selective with minimal side effects.subcutaneousInvestigational / RUO
    KisspeptinA neuroendocrine peptide that activates KISS1R (GPR54) on GnRH neurons to stimulate gonadotropin-releasing hormone secretion, a key upstream regulator of the reproductive axis.subcutaneousInvestigational / RUO

    Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.

    FAQ

    Frequently asked questions

    Research-use notice

    Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.

    Cited guide source: View source

    How these protocol references are compiled·About this library